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Background: Tumor necrosis factor-alpha (TNF-α) can induce cardiogenic transformation of normal adult mesenchymal stem cells. It is unknown 
whether this differentiation capacity remains active in the presence of heart failure (HF). This study tested whether bone marrow mesenchymal stem 
cells (BMMSC) harvested from dogs with HF and exposed to TNF-α also undergo cardiogenic transformation.
Methods: Bone marrow was extracted from dogs with coronary microembolization-induced HF. BMMSC were obtained using the Ficoll method and 
cultured in Iscove’s Modified Dulbecco’s Medium (IMDM). The BMMSC were then incubated in IMDM alone (control) or IMDM with TNF-α 100 ng/
ml for 1, two, three and 4 weeks. Cardiogenic transformation was evaluated by measuring expression of cardiac transcription factor Nkx2.5 and 
α-actinin using immunofluorescence.
Results: The expression of Nkx2.5 and α-actinin was higher in the TNF-α treated BMMSC compared with control. The number of Nkx2.5 (+) cells 
peaked at 2 weeks, declined at 3 weeks and it was zero at 4 weeks. The number of α-actinin (+) cells increased with time: at 1 week was 11% in the 
TNF-α treated cells vs 1% in control, at 2 weeks 32% vs 6%, at 3 weeks 66% vs 11% and at 4 weeks 80% vs 14%.
Conclusions: TNF-α induces cardiogenic transformation of BMMSC obtained from dogs with chronic HF. Our findings suggest that when TNF-α 
mediated cardiogenic transformation of BMMSC is contemplated as a therapeutic option in HF, an autologous approach is possible avoiding the 
need for a BMMSC donor pool.
